Compare Vanguard Total Bond Market Index Fund ETF (BND) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total Bond Market Index Fund ETF vs Mesoblast Limited — how do they compare? Vanguard Total Bond Market Index Fund ETF trades at $72.25, while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Mesoblast Limited is trading nearer its 52-week high, Vanguard Total Bond Market Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| BND | MESO | |
|---|---|---|
52-Week High | $75.17 | $20.96 |
52-Week Low | $72.15 | $12.88 |
Market Cap | — | $2.16B |
Sector | — | Technology |
Enterprise Value | — | $2.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BND trades at $72.4, up 0.21% today, with a neutral technical signal from indicators like RSI near 50. Recent news highlights institutional activity, including Boston Standard Wealth reducing its stake by 30.6% in Q2 2026 (SEC filing, August 5, 2026), while Arkadios Wealth increased holdings by 41.9% (SEC filing, July 30, 2026). The bond ETF faces headwinds from rising Treasury yields and inflation concerns, as noted in financial media.
Outlook is cautious due to interest rate sensitivity and macroeconomic volatility. Risks include Fed policy shifts and oil price fluctuations, but BND offers diversification and steady dividends, with recent payouts around $0.24-$0.25. Investors should weigh income benefits against bond market pressures.
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard Total Bond Market Index Fund ETF
This index measures the performance of a wide spectrum of public, investment-grade, taxable, fixed income securities in the US, including government, corporate, and international dollar-denominated bonds, as well as mortgage-backed and asset-backed securities-all with maturities of more than 1 year. All of the fund's investments will be selected through the sampling process, and at least 80% of its assets will be invested in bonds held in the index.
Read more on BND →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
